View New Articles By
Carla Koehler, PhD (Damon Runyon Fellow '95-'98 and Scholar '99-'02) of the University of California, Los Angeles, was named an American Association for the Advancement of Science Fellow for significant contributions in characterizing mechanisms of protein and RNA transport in the mitochondria. The tradition of AAAS Fellows dates to 1874 and comprises an illustrious group of scientists, including many Nobel Laureates.
Nicholas Arpaia, PhD (Damon Runyon Fellow '12-'16) of Columbia University, and his colleague received the $500,000 prize to support research on designing probiotic bacterial strains that find and attack lung cancer. The Young Innovator Team Awards were established in 2014 to encourage out-of-the-box thinking and foster leadership skills among young researchers, instilling confidence in them to drive breakthrough lung cancer research using a collaborative, cross-institutional approach.
The Damon Runyon-Jake Wetchler Award for Pediatric Innovation is given annually to a third-year Damon Runyon Fellow whose research has the greatest potential to impact the prevention, diagnosis or treatment of pediatric cancer. In its third year, Challice L. Bonifant, MD, PhD, received this special award at the annual Fellows' Retreat.
Approximately 450 supporters took part in Runyon Up, the first fundraising stair climb held at the newly opened Salesforce Tower in San Francisco on October 21. Climbers faced a unique vertical challenge in the 61-story building, the tallest in San Francisco, and were rewarded with breathtaking views from the top.
Patients with metastatic breast cancer—when the tumor has spread to other organs in the body—face a terminal prognosis and toxic treatments. There is an urgent need for new ways to treat drug metastatic and resistant stages of the disease. Sarat Chandarlapaty, MD, PhD (Clinical Investigator ’12-’17), and colleagues, have developed a novel class of drugs that may help these patients by potentially stopping or even destroying breast cancer tumors.
Two Damon Runyon alumni were elected to the National Academy of Medicine. Election to the Academy is considered one of the highest honors in the fields of health and medicine and recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.
Azad Bonni, MD, PhD (Damon Runyon Fellow ’96-‘97) at the Washington University School of Medicine, St. Louis, was recognized for discovering fundamental signaling networks governing brain development and how deregulation of these circuits contributes to cognitive disorders.
By Yung S. Lie, PhD, Incoming President and Chief Executive Officer of the Damon Runyon Cancer Research Foundation
Damon Runyon congratulates the recipients of the 2018 Nobel Prize in Physiology or Medicine, James P. Allison and Tasuku Honjo, for their discovery that certain proteins act as “brakes” on the immune system, limiting its ability to attack cancer cells. Drugs called checkpoint inhibitors have since been developed to take these brakes off, freeing the immune cells to fight cancer and save countless lives. The field of checkpoint inhibition, as well as the entire field of immunotherapy (harnessing the immune system to recognize and attack cancer cells), has exponentially grown in importance due to the contributions of a community of many scientists. We are proud to have supported several Damon Runyon scientists, who have made critical discoveries that have helped bring this new class of drugs to patients.
Triple negative breast cancer (TNBC) is the most aggressive and hard-to-treat form of breast cancer. Doctors have observed that TNBC patients with higher numbers of immune cells in their tumors seem to have better survival than those with fewer, but it's not well understood why. Damon Runyon Fellow Leeat Yankielowicz-Keren, PhD, and Dale F. Frey Breakthrough Scientist Sean C.
One of the greatest challenges doctors face is predicting, which patients will respond to a particular cancer therapy. Ash Alizadeh, MD, PhD (Damon Runyon Clinical Investigator '14 - '17) and David Kurtz, MD, PhD (Damon Runyon Physician Scientist '16 - '20), at Stanford University School of Medicine have developed a new blood test to guide doctors when treating diffuse large B cell lymphoma (DLBCL). This research was published in the Journal of Clinical Oncology.
To mark Damon Runyon’s upcoming 75th Anniversary in 2021, Connie and Bob Lurie have established a $1 million “Connie and Robert Lurie Breakthrough Challenge Fund” to generate new support for Damon Runyon scientists working at Stanford, UCSF, UC Berkeley, the Gladstone Institute and UC Santa Cruz. Connie and Bob, and the entire Lurie family, are a Bay Area institution. Many know them as leaders in the world of commercial real estate, for their generous philanthropy, or for saving the Giants from moving to Toronto by purchasing the team in 1976. What you might not know is how committed they are to finding cures for cancer and supporting new generations of breakthrough scientists in the Bay Area. They are now partnering with Damon Runyon to build support for our many Bay Area researchers.
CONNECT
1.877.7CANCER
info@damonrunyon.org
One Exchange Plaza
55 Broadway, Suite 302
New York, NY 10006
